| ¿µ¹® | acute hepatitis | ÇÑ±Û | ±Þ¼º°£¿° |
|---|---|---|---|
| ¼³¸í | ¹ÙÀÌ·¯½º¿¡ ÀÇÇØ °£¿¡ »ý±â´Â ±Þ¼º¿°Áõ. ±Þ¼º°£¿°À̶õ °£¿°¹ÙÀÌ·¯½º(AÇü-BÇü-ºñAºñBÇü)¿¡ ÀÇÇØ¼ °£¿¡ »ý±â´Â ±Þ¼º¿°ÁõÀ» º´¸íÀ¸·Î À̸£´Â ¸»·Î, ÀÌ´Â ±× °¨¿°¾ç½Ä¿¡ ¼öÇ÷ ÈÄ¿¡ ¹ß»ýÇÏ´Â ¼öÇ÷ÈÄ °£¿°°ú, °¨¿°°æ·Î¸¦ ¾Ë ¼ö ¾ø´Â »ê¹ß¼º°£¿° ¹× Áý´ÜÀ¸·Î ¹ß»ýÇÏ´Â À¯Ç༱°£¿°ÀÇ ¼¼°¡Áö À¯ÇüÀ¸·Î ³ª´ ¼ö ÀÖ´Ù. ¼öÇ÷ÈÄ °£¿°Àº ±× 95%°¡ ºñAºñBÇü°£¿°ÀÌ¸ç ³ª¸ÓÁö°¡ BÇü °£¿°ÀÌ´Ù. »ê¹ß¼º °£¿°Àº AÇü °£¿°°ú BÇü °£¿°ÀÌ °¢°¢ 30%¸¦ ÀÌ·ç°í ³ª¸ÓÁö 40%´Â ºñAºñB°£¿°ÀÌ´Ù. Áý´ÜÀ¸·Î ¹ß»ýÇÏ´Â À¯Ç༺°£¿°Àº °ÅÀǰ¡ AÇü°£¿°ÀÌÁö¸¸ ¶§·Î´Â ¿©±â¿¡ Æ÷ÇÔµÇÁö ¾ÊÀº ÇüÀÇ °£¿°ÀÏ °æ¿ìµµ ÀÖ´Ù. ±Þ¼º°£¿°ÀÇ Áõ¼¼´Â ¸ÕÀú ¸öÀÌ ³ª¸¥ÇØÁö°í ¿Â¸ö¿¡ ±ÇۨÀÌ Ã£¾Æ¿À¸ç Á¶±×¸¶ÇÑ ÀÏ¿¡µµ °ð ÇǷθ¦ ´À³¢°Ô µÈ´Ù. ±×¸®°í ½Ä¿åºÎÁø-¹ß¿-±¸ÅäÁõ-º¹Åë-¼³»ç µî, °¨±â³ª ±Þ¼ºÀ§Àå¿°¿¡ °É·ÈÀ» ¶§¿Í °°Àº Áõ¼¼ µîÀÌ ³ªÅ¸³´Ù. µÚÀ̾î Ȳ´ÞÁõ¼¼¸¦ º¸À̴µ¥, À̶§´Â ÃʱâÀÇ Áõ¼¼°¡ ¾à°£ °¡º¿öÁø °Íó·³ ´À²¸Áö´Â °ÍÀÌ º¸ÅëÀÌ´Ù. ±×·¯³ª Ȳ´ÞÁõ¼¼°¡ ½ÉÇØÁö°í ÃʱâÀÇ Áõ¼¼µéÀÌ ´Ù½Ã ÁøÇàµÇ¸é À̶§´Â Àü°Ý¼º°£¿°ÀÌ µÉ À§ÇèÀÌ ÀÖ´Ù. °£¿° Áõ¼¼°¡ ½ÉÇÏÁö ¾Ê¾ÒÀ» °æ¿ì´Â Ȳ´ÞÀÌ ´«¿¡ ¶çÁö ¾ÊÀº °æ¿ìµµ Àִµ¥ À̶§´Â ÁøÂûÀ» ÇØµµ °¨±â³ª ±Þ¼ºÀ§Ã¢ÀÚ¿°À¸·Î ÀÚÄ© ¿ÀÁøµÇ±â ½±´Ù. ¶Ç AÇü°£¿°Àº ¿ÀÌ 38~39¡É±îÁö ¿À¸£°í Áõ¼¼°¡ °©Àڱ⠳ªÅ¸³ª´Â °ÍÀÌ Æ¯Â¡ÀÌ¸ç ±Þ¼ººñAºñBÇü°£¿°Àº Áõ¼¼°¡ ºñ±³Àû °¡º¿î °ÍÀÌ Æ¯Â¡ÀÌ´Ù. ±Þ¼ºBÇü°£¿°ÀÇ Áõ¼¼´Â AÇü°£¿°°ú ±Þ¼ººñAºñBÇü°£¿°ÀÇ Áß°£ Á¤µµÀÎ °ÍÀÌ º¸ÅëÀÌ´Ù. |
||
| ¿µ¹® | acute appendicitis | ÇÑ±Û | ±Þ¼º¸·Ã¢ÀÚ²¿¸®¿° |
|---|---|---|---|
| ¼³¸í | ¿Ü°úÀû óġ¸¦ ¿äÇÏ´Â ¸·Ã¢ÀÚ²¿¸®(Ãæ¼ö)ÀÇ ±Þ¼º¿°ÁõÀ¸·Î¼, º¸Åë ÇϺ¹ºÎÀÇ ¿À¸¥ÂÊ 1/4 ºÎÀ§¿¡¼ÀÇ ÅëÁõÀÌ Æ¯Â¡À̸ç, ±¹¼Ò¾ÐÅë, ±ÙÀ°±äÀå ÇǺΰ¨°¢ÀÇ °ú¹Î µîÀ» ¼ö¹ÝÇÑ´Ù. ÀϹݵòµéÀÌ ¡°¸ÍÀå¿°¡±À̶ó°í ÇÏ´Â °ÍÀ¸·Î ¸ÍÀå¿°Àº ¸·Ã¢ÀÚÀÇ ¿°ÁõÀ¸·Î ±¸º°µÇ¾î¾ß ÇÑ´Ù. ¹ß¿°ú ´ÙÇü¹éÇ÷±¸Áõ´Ù´Â ±¹¼Ò°¨¿°ÀÇ °á°úÀÌ´Ù. ¸·Ã¢ÀÚ²¿¸®ÀÇ À§Ä¡-À¯Âø»óÅÂ-²¿ÀÓ µî¿¡ ÀÇÇØ Áõ»ó°ú ¡ÈÄ´Â º¯µ¿µÈ´Ù. |
||
| ¿µ¹® | acute cholecystitis | ÇÑ±Û | ±Þ¼º¾µ°³¿° |
|---|---|---|---|
| ¼³¸í | º¸Åë ¾µ°³ ÃⱸÀÇ Æó»ö¿¡ ÀÇÇÑ °ÍÀ̸ç, ¿°ÁõÀÇ Á¤µµ´Â °æµµÀÇ ºÎÁ¾À¸·ÎºÎÅÍ ±«Àú¿Í õ°øÀ» ¼ö¹ÝÇÏ´Â °¨¿°Áõ±îÁö ÀÖ´Ù. |
||
| ¿µ¹® | severe acute respiratory syndrome(SARS) | ÇÑ±Û | »ç½º |
|---|---|---|---|
| ¼³¸í | Áß±¹ ±¤µ¿ Áö¿ª¿¡¼ °¡Àå ¸ÕÀú ¹ß»ýÇÑ Àü¿°¼º È£Èí±â ÁúȯÀ¸·Î ¼¼°èº¸°Ç±â±¸(WHO)¿¡¼ ¡®ÁßÁõ±Þ¼ºÈ£ÈíÁõÈıº(SARS)'À¸·Î ¸í¸íÇß´Ù. ¼·¾¾ 38µµ ÀÌ»óÀÇ °í¿°ú ±âħ, È£Èí°ï¶õ, Àú»ê¼ÒÁõ, X¼±»óÀÇ Æó·ÅÁõ»ó Áß Çϳª ÀÌ»óÀÇ Áõ»óÀÌ ³ªÅ¸³ª¸ç, µÎÅë, ±ÙÀ°Åë, ½Ä¿åºÎÁø, ÇǷΰ¨, ¹ßÁø, ¼³»ç¸¦ µ¿¹ÝÇÒ ¼ö ÀÖ´Ù. Ãʱâ Áõ»óÀº °¨±â¿Í ºñ½ÁÇÏÁö¸¸ Æó·ÅÀ¸·Î ¹ßÀüÇϸé Ä¡¸íÀûÀÏ ¼ö ÀÖ´Ù. ÇöÀç ¹àÇôÁø °¨¿°°æ·Î´Â ȯÀÚ°¡ Àçä±â³ª ±âħÇÒ ¶§ ³»»Õ´Â ħ¹æ¿ïÀ̰í, À̰ÍÀÌ ´Ù¸¥ »ç¶÷ÀÇ È£Èí±â·Î µé¾î°¥ ¶§ Àü¿°µÈ´Ù. ħ¹æ¿ïÀÌ Àü´ÞµÇ´Â °Å¸®´Â º¸Åë 1m·Î º¸°í ÀÖ´Ù. °ø±â¸¦ ÅëÇØ Àü¿°ÀÌ °¡´ÉÇÏ´Ù´Â ÁÖÀåÀÌ Á¦±âµÆÁö¸¸ ¾ÆÁ÷ È®ÀεÇÁö ¾Ê¾Ò´Ù. ¿øÀαÕÀº º¯Á¾ Äڷγª¹ÙÀÌ·¯½º·Î ¹àÇôÁ³´Ù. |
||
| ¿µ¹® | severe acute respiratory syndrome(SARS) | ÇÑ±Û | ÁßÁõ±Þ¼ºÈ£ÈíÁõÈıº |
|---|---|---|---|
| ¼³¸í | Áß±¹ ±¤µ¿ Áö¿ª¿¡¼ °¡Àå ¸ÕÀú ¹ß»ýÇÑ Àü¿°¼ºÈ£Èí±âº´À¸·Î ¼¼°èº¸°Ç±â±¸(WHO)¿¡¼ ¡®ÁßÁõ±Þ¼ºÈ£ÈíÁõÈıº(SARS)'À¸·Î ¸í¸íÇß´Ù. ¼·¾¾ 38µµ ÀÌ»óÀÇ °í¿°ú ±âħ, È£Èí°ï¶õ, Àú»ê¼ÒÁõ, X¼±»óÀÇ Æó·ÅÁõ»ó Áß Çϳª ÀÌ»óÀÇ Áõ»óÀÌ ³ªÅ¸³ª¸ç, µÎÅë, ±ÙÀ°Åë, ½Ä¿åºÎÁø, ÇǷΰ¨, ¹ßÁø, ¼³»ç¸¦ µ¿¹ÝÇÒ ¼ö ÀÖ´Ù. Ãʱâ Áõ»óÀº °¨±â¿Í ºñ½ÁÇÏÁö¸¸ Æó·ÅÀ¸·Î ¹ßÀüÇϸé Ä¡¸íÀûÀÏ ¼ö ÀÖ´Ù. ÇöÀç ¹àÇôÁø °¨¿°°æ·Î´Â ȯÀÚ°¡ Àçä±â³ª ±âħÇÒ ¶§ ³»»Õ´Â ħ¹æ¿ïÀ̰í, À̰ÍÀÌ ´Ù¸¥ »ç¶÷ÀÇ È£Èí±â·Î µé¾î°¥ ¶§ Àü¿°µÈ´Ù. ħ¹æ¿ïÀÌ Àü´ÞµÇ´Â °Å¸®´Â º¸Åë 1m·Î º¸°í ÀÖ´Ù. °ø±â¸¦ ÅëÇØ Àü¿°ÀÌ °¡´ÉÇÏ´Ù´Â ÁÖÀåÀÌ Á¦±âµÆÁö¸¸ ¾ÆÁ÷ È®ÀεÇÁö ¾Ê¾Ò´Ù. ¿øÀαÕÀº º¯Á¾ Äڷγª¹ÙÀÌ·¯½º·Î ¹àÇôÁ³´Ù. |
||
| ECG | Electro-Cardio-Graphy(-Gram); ½ÉÀüµµ = EKG 1. Conducting System Structu... |
|---|---|
| AML | Acute Myelogenous Leukemia Morphologic Classification(FABºÐ·ù) &n... |
| AER | abduction/external rotation; acoustic evoked response; acute exertional rhabdomyolysis; agranular en... |
| AP | accessory pathway; accounts payable; acid phosphatase; acinar parenchyma; action potential; active p... |
| AML | acute monocytic leukemia; acute mucosal lesion; acute myeloblastic leukemia; acute myelocytic leukem... |
| APRF | 3/acute phase response factor |
|---|---|
| APR | Acute Phase Response |
| APRE | acute phase response element |
| Phase I | phase |
| S phase | synthesis phase |
acute angle
acute arthritis
acute monocytic leukemia
| early-phase response | Prompt onset of symptoms following an antigenic stimulus. (05 Mar 2000) |
|---|---|
| late-phase response | Recurrence of symptoms after an appreciable interval following challenge with an antigen; preceded by an initial early-phase response. (05 Mar 2000) |
| acute-phase protein | <haematology> These plasma proteins (in addition to fibrinogen) increase 25% or more in response to inflammation and injury are under direct control of interleukin-6 (IL-6) (hepatocyte-stimulating factor). Other proteins which increase are ceruloplasmin, C3 and C4 which increase 50% or more; alpha-1 acid glycoprotein, alpha-1 antitrypsin, haptoglobin and fibrinogen (the major determinant of viscosity 1 ) which increase two- to fourfold; C-reactive protein (CRP) and serum amyloid A which increase several hundred-fold. Despite long-held clinical opinion to the contrary, available data indicate that neither ESR nor measurement of specific acute-phase reactants are useful in excluding underlying infection or inflammation regardless of the pretest probability. These proteins are secreted into the blood in increased or decreased quantities by hepatocytes in response to trauma, inflammation, or disease. They can serve as inhibitors or mediators of the inflammatory processes. Certain acute-phase proteins have been used to diagnose and follow the course of diseases or as tumour markers. See also: amyloid, c-reactive protein, erythrocyte sedimentation rate, viscosity. (25 Jun 1999) |
| acute-phase reaction | <immunology, rheumatology> Refers to the changes in synthesis of certain proteins within the serum during an inflammatory response, which provides rapid protection for the host against microorganisms via non-specific defense mechanisms. It consists of fever, an increase in inflammatory humoral factors, and an increased synthesis by hepatocytes of a number of proteins or glycoproteins usually found in the plasma; the reaction is mediated by endogenous pyrogens, the hypothalamus, adrenal hormones, and other factors. (12 Jul 2000) |
| anamnestic response | <immunology> Archaic term now replaced by such terms as secondary immune response, immune memory. (18 Nov 1997) |
| audiometry, evoked response | A form of electrophysiologic audiometry in which an analog computer is included in the circuit to average out ongoing or spontaneous brain wave activity. A characteristic pattern of response to a sound stimulus may then become evident. Evoked response audiometry is known also as electric response audiometry. (12 Dec 1998) |
| auditory brainstem response audiometry | An electrophysiologic measure of auditory function utilizing responses produced by the auditory nerve and the brainstem to repetitive acoustic stimuli. (05 Mar 2000) |
| biological response modifier | <pharmacology, oncology> A substance used in adjuvant therapy that takes advantage of the bodys own natural defense mechanisms to inhibit the growth of a tumour. (16 Dec 1997) |
| biological response modifiers | Substances that stimulate the body's response to infection and disease. The body naturally produces small amounts of these substances. Scientists can produce some of them in the laboratory in large amounts and use them in cancer treatment. Also called BRMs. (12 Dec 1998) |
| biphasic response | Two separate and distinct responses that are separated in time, immediate reaction to an antigenic challenge followed by a recurrence of symptoms after an interval of quiescence. (05 Mar 2000) |
| booster response | The response of the immune system to the second or subsequent occasion on which it encounters a specific antigen. (18 Nov 1997) |
| brainstem evoked response audiometry | An electrophysiologic measure of auditory function utilizing responses produced by the auditory nerve and the brainstem to repetitive acoustic stimuli. (05 Mar 2000) |
| galvanic skin response | A change in electrical resistance of the skin, occurring in emotion and in certain other conditions. (12 Dec 1998) |
| recruiting response | <neurology> The gradual increase to a maximum in a reflex when a stimulus of unaltered intensity is prolonged. (12 Dec 1998) |
| partial response | <oncology> A decrease of at least 50 percent in the sum of the measurements of all evaluable target lesions or tumours seen in a study. (16 Dec 1997) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|